文献速递青光眼

3期随机对照研究:10微克前房内比马前列素植入物与选择性激光小梁成形术的比较

Phase 3, Randomized, Comparison Study of Intracameral Bimatoprost Implant 10 µg and Selective Laser Trabeculoplasty.
PubMed 文献 · Am J Ophthalmol · 2025-01-10

这项3期随机、24个月、多中心、患者与疗效评估者设盲的对眼临床试验纳入183例开角型青光眼或高眼压症患者,一眼接受360°选择性激光小梁成形术(SLT),对侧眼接受10微克比马前列素植入物(最多2次给药)。结果显示,在第4、12、24周,植入物组较基线的眼压降幅与SLT组相比达到统计学和临床非劣效;灵活再给药方案改善了植入物的安全性。

要点

  • 第4、12、24周,植入物组眼压降幅分别为6.8、6.9、6.9 mmHg,SLT组分别为6.2、6.4、6.5 mmHg,植入物非劣效于SLT。
  • 第360天和720天未需补救治疗的概率:植入物组67.5%和50.2%,SLT组68.7%和60.6%。
  • 第24个月角膜内皮细胞密度较基线变化:植入物组-6.2%,SLT组-3.1%;灵活再给药组-5.2%,固定再给药组-7.9%。

核心结论

  • 比马前列素植入物在第4、12、24周眼压较基线降幅上达到对SLT的统计学和临床非劣效。
  • 亚组分析中,灵活再给药的患者满足相同标准。
  • 植入物和SLT在许多眼中均显示持续2年的眼压降低。
  • 灵活给药方案较固定给药方案改善了植入物的安全性。

研究设计与样本

  • 3期(Stage 2)、随机、24个月、多中心、患者与疗效评估者设盲的对眼临床试验(NCT02507687)。
  • 共纳入183例开角型青光眼或高眼压症患者,因疗效以外原因使用局部降眼压药物管理不佳。
  • 一眼接受单次360° SLT,对侧眼接受10微克比马前列素植入物。
  • 植入物眼最初在第16周若符合安全性标准则接受第二次植入;方案修订后,若眼压>17 mmHg且符合安全性标准则按灵活计划再治疗。

主要发现

  • 植入物组和SLT组基线平均眼压分别为25.2±0.22 mmHg和25.1±0.22 mmHg。
  • 第4周眼压较基线最小二乘均值降幅:植入物组6.8±0.28 mmHg vs SLT组6.2±0.28 mmHg。
  • 第12周眼压较基线最小二乘均值降幅:植入物组6.9±0.30 mmHg vs SLT组6.4±0.30 mmHg。
  • 第24周眼压较基线最小二乘均值降幅:植入物组6.9±0.27 mmHg vs SLT组6.5±0.28 mmHg。
  • 第360天和720天未需非研究性(补救)降眼压治疗的概率:植入物组67.5%和50.2%,SLT组68.7%和60.6%。

关键数值与推荐

  • 主要疗效指标为眼压较基线变化,主要时间点为第4、12、24周。
  • 第24个月角膜内皮细胞密度较基线平均百分比变化:植入物组-6.2±1.13%,SLT组-3.1±0.43%。
  • 植入物组中,固定再给药亚组角膜内皮细胞密度变化为-7.9±2.04%,灵活再给药亚组为-5.2±1.35%。
  • 植入物组和SLT组最常见的眼部治疗中出现的不良事件均为归因于疗效减退的眼压升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the intraocular pressure (IOP)-lowering effect and safety of up to 2 bimatoprost implant administrations versus selective laser trabeculoplasty (SLT). DESIGN: Phase 3 (Stage 2), randomized, 24-month, multicenter, patient- and efficacy evaluator-masked, paired-eye clinical trial (NCT02507687). PARTICIPANTS: Patients (n = 183) with open-angle glaucoma or ocular hypertension inadequately managed with topical IOP-lowering medication for reasons other than efficacy. INTERVENTION: Patients received a single 360° SLT procedure in 1 eye and 10-µg bimatoprost implant administration in the contralateral eye. Initially, implant-treated eyes received a second implant at week 16 if safety criteria were met. After a protocol amendment, implant-treated eyes were retreated with flexible scheduling if IOP was >17 mm Hg and safety criteria were met. MAIN OUTCOME MEASURES: The primary efficacy variable was IOP change from baseline, with primary timepoints at weeks 4, 12, and 24. Safety measures included treatment-emergent adverse events (TEAEs) and ocular safety measures. RESULTS: Mean (±SE) baseline IOP (mm Hg) was 25.2 ± 0.22 and 25.1 ± 0.22 in implant- and SLT-treated eyes, respectively. Least-squares mean (±SE) IOP reduction from baseline (mm Hg) for eyes treated with up to 2 implants versus SLT was 6.8 ± 0.28 versus 6.2 ± 0.28 at week 4, 6.9 ± 0.30 versus 6.4 ± 0.30 at week 12, and 6.9 ± 0.27 versus 6.5 ± 0.28 at week 24. The probability of not having required nonstudy (rescue) IOP-lowering treatment at days 360 and 720, respectively, was 67.5% and 50.2% for implant-treated eyes versus 68.7% and 60.6% for SLT-treated eyes. The most common ocular TEAE in both implant- and SLT-treated eyes was increased IOP attributed to wearing off of efficacy. Mean (±SE) percentage change in corneal endothelial cell density from baseline at month 24 was -6.2 ± 1.13% in implant-treated eyes (-7.9 ± 2.04% with fixed readministration; -5.2 ± 1.35% with flexible readministration) versus -3.1 ± 0.43% in SLT-treated eyes. CONCLUSIONS: The bimatoprost implant demonstrated statistical and clinical noninferiority to SLT in IOP reduction from baseline at weeks 4, 12, and 24. In subgroup analysis, patients with flexible implant readministration met the same criteria. Both the implant and SLT demonstrated sustained (2-year) IOP lowering in many eyes. A flexible administration schedule improved the safety profile of the implant over the fixed administration schedule.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Kolko M, Tatham AJ, Lim KS, et al. Phase 3, Randomized, Comparison Study of Intracameral Bimatoprost Implant 10 µg and Selective Laser Trabeculoplasty. Am J Ophthalmol. 2025. PMID: 39800203. doi:10.1016/j.ajo.2024.12.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。